{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:02:03Z","timestamp":1791662523464,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Increasing evidence supports the role of soluble inflammatory mediators in the pathogenesis of refractory temporal lobe epilepsy (TLE). Hippocampal sclerosis (HS) is a well-described pathohistological abnormality in TLE. The association of proinflammatory cytokines with epileptic disease profiles is well established; however, the potential significance of circulating interleukin 10 (IL-10), particularly in TLE-associated HS, is still poorly understood. Therefore, taking into consideration the neuroprotective and anticonvulsive effects of IL-10, we performed this study to examine the role of the plasma levels of IL-10 in patients with TLE with HS (TLE\u2009+\u2009HS), TLE without HS (TLE-HS) and with other types of epilepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included 270 patients with refractory epilepsy who were classified into four groups: i) 34 patients with TLE\u2009+\u2009HS, ii) 105 patients with TLE-HS, iii) 95 patients with extra-TLE (XLE) and iv) 36 patients with idiopathic generalized epilepsy (IGE). The plasma IL-10 levels were quantified using a commercially available enzyme-linked immunosorbent assay (ELISA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IL-10 levels were significantly lower in TLE\u2009+\u2009HS than in TLE-HS (<jats:italic>p<\/jats:italic>\u2009=\u20090.013). In a subgroup of TLE-HS patients who had seizures 1 month before sampling, patients with seizures had significantly higher IL-10 levels than patients who were seizure-free (<jats:italic>p<\/jats:italic>\u2009=\u20090.039). Among a small group (<jats:italic>n<\/jats:italic>\u2009=\u200915) of non-refractory TLE-HS patients, IL-10 levels showed a moderate negative correlation with the duration of epilepsy (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u20090.585,<jats:italic>p<\/jats:italic>\u2009=\u20090.023).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrated that chronically reduced levels of plasma IL-10 were associated with HS in TLE patients, suggesting that there was an inadequate systemic anti-inflammatory immune response. These results could provide new biological insights into the pathophysiology of HS in TLE. We also found that the production of IL-10 could be affected by the seizure frequency and declined concomitantly with increased disease durations. Therefore, the measurement of plasma IL-10 may have diagnostic value as a biomarker for stratifying TLE\u2009+\u2009HS from other epilepsy types or as a marker of disease progression towards a progressive form of epilepsy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-020-01825-x","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T07:02:43Z","timestamp":1591945363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Chronically reduced IL-10 plasma levels are associated with hippocampal sclerosis in temporal lobe epilepsy patients"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2239-7681","authenticated-orcid":false,"given":"Pabitra","family":"Basnyat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Pesu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"S\u00f6derqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gr\u00f6nholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Liimatainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Peltola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Raitanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Peltola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"issue":"8","key":"1825_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","volume":"15","author":"A Vezzani","year":"2019","unstructured":"Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15(8):459\u201372.","journal-title":"Nat Rev Neurol"},{"key":"1825_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.expneurol.2011.09.033","volume":"244","author":"A Vezzani","year":"2013","unstructured":"Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11\u201321.","journal-title":"Exp Neurol"},{"issue":"5","key":"1825_CR3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/bmm.11.61","volume":"5","author":"A Vezzani","year":"2011","unstructured":"Vezzani A, Friedman A. Brain inflammation as a biomarker in epilepsy. Biomark Med. 2011;5(5):607\u201314.","journal-title":"Biomark Med"},{"issue":"1","key":"1825_CR4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yfrne.2011.12.002","volume":"33","author":"MA Galic","year":"2012","unstructured":"Galic MA, Riazi K, Pittman QJ. Cytokines and brain excitability. Front Neuroendocrinol. 2012;33(1):116\u201325.","journal-title":"Front Neuroendocrinol"},{"issue":"5","key":"1825_CR5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-009-5021-x","volume":"256","author":"S Liimatainen","year":"2009","unstructured":"Liimatainen S, Fallah M, Kharazmi E, Peltola M, Peltola J. Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy. J Neurol. 2009;256(5):796\u2013802.","journal-title":"J Neurol"},{"issue":"1\u20132","key":"1825_CR6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jns.2009.02.355","volume":"280","author":"T Alapirtti","year":"2009","unstructured":"Alapirtti T, Rinta S, Hulkkonen J, Makinen R, Keranen T, Peltola J. Interleukin-6, interleukin-1 receptor antagonist and interleukin-1beta production in patients with focal epilepsy: a video-EEG study. J Neurol Sci. 2009;280(1\u20132):94\u20137.","journal-title":"J Neurol Sci"},{"key":"1825_CR7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.12.008","volume":"316","author":"T Alapirtti","year":"2018","unstructured":"Alapirtti T, Lehtimaki K, Nieminen R, Makinen R, Raitanen J, Moilanen E, et al. The production of IL-6 in acute epileptic seizure: a video-EEG study. J Neuroimmunol. 2018;316:50\u20135.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"1825_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.08.001","volume":"263","author":"S Liimatainen","year":"2013","unstructured":"Liimatainen S, Lehtimaki K, Palmio J, Alapirtti T, Peltola J. Immunological perspectives of temporal lobe seizures. J Neuroimmunol. 2013;263(1\u20132):1\u20137.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1825_CR9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12974-016-0763-8","volume":"13","author":"D Lobo-Silva","year":"2016","unstructured":"Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation. 2016;13(1):297\u2013016.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"1825_CR10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1825_CR11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377.","journal-title":"Epilepsia"},{"key":"1825_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1742-2094-9-207","volume":"9","author":"AA Kan","year":"2012","unstructured":"Kan AA, de Jager W, de Wit M, Heijnen C, van Zuiden M, Ferrier C, et al. Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines. J Neuroinflammation. 2012;9:207\u20132094.","journal-title":"J Neuroinflammation"},{"key":"1825_CR13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fncel.2015.00466","volume":"9","author":"WA Alsharafi","year":"2015","unstructured":"Alsharafi WA, Xiao B, Abuhamed MM, Bi FF, Luo ZH. Correlation between IL-10 and microRNA-187 expression in epileptic rat hippocampus and patients with temporal lobe epilepsy. Front Cell Neurosci. 2015;9:466.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"1825_CR14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12974-016-0727-z","volume":"13","author":"KI Strauss","year":"2016","unstructured":"Strauss KI, Elisevich KV. Brain region and epilepsy-associated differences in inflammatory mediator levels in medically refractory mesial temporal lobe epilepsy. J Neuroinflammation. 2016;13(1):270.","journal-title":"J Neuroinflammation"},{"issue":"13","key":"1825_CR15","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra022308","volume":"349","author":"BS Chang","year":"2003","unstructured":"Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003;349(13):1257\u201366.","journal-title":"N Engl J Med"},{"issue":"5","key":"1825_CR16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/nan.12150","volume":"40","author":"M Thom","year":"2014","unstructured":"Thom M. Review: hippocampal sclerosis in epilepsy: a neuropathology review. Neuropathol Appl Neurobiol. 2014;40(5):520\u201343.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1825_CR17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fncel.2018.00458","volume":"12","author":"AR Burmeister","year":"2018","unstructured":"Burmeister AR, Marriott I. The Interleukin-10 family of cytokines and their role in the CNS. Front Cell Neurosci. 2018;12:458.","journal-title":"Front Cell Neurosci"},{"key":"1825_CR18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1742-2094-5-23","volume":"5","author":"JJ Jin","year":"2008","unstructured":"Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2008;5:23.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1825_CR19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12974-019-1452-1","volume":"16","author":"Y Sun","year":"2019","unstructured":"Sun Y, Ma J, Li D, Li P, Zhou X, Li Y, et al. Interleukin-10 inhibits interleukin-1beta production and inflammasome activation of microglia in epileptic seizures. J Neuroinflammation. 2019;16(1):66\u2013019.","journal-title":"J Neuroinflammation"},{"key":"1825_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/epi4.12242","volume":"3","author":"T Ravizza","year":"2018","unstructured":"Ravizza T, Vezzani A. Pharmacological targeting of brain inflammation in epilepsy: therapeutic perspectives from experimental and clinical studies. Epilepsia Open. 2018;3:133\u201342.","journal-title":"Epilepsia Open"},{"issue":"2","key":"1825_CR21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-510X(02)00420-3","volume":"206","author":"HF Petereit","year":"2003","unstructured":"Petereit HF, Pukrop R, Fazekas F, Bamborschke SU, Ropele S, Kolmel HW, Merkelbach S, Japp G, Jongen PJ, Hartung HP, Hommes OR. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. J Neurol Sci. 2003;206(2):209\u201314.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"1825_CR22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jneuroim.2003.10.033","volume":"146","author":"SS Soldan","year":"2004","unstructured":"Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol. 2004;146(1\u20132):209\u201315.","journal-title":"J Neuroimmunol"},{"key":"1825_CR23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/B978-0-444-64076-5.00046-6","volume":"148","author":"C Cotsapas","year":"2018","unstructured":"Cotsapas C, Mitrovic M, Hafler D. Multiple sclerosis. Handb Clin Neurol. 2018;148:723\u201330.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"1825_CR24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12974-017-0974-7","volume":"14","author":"K Kim","year":"2017","unstructured":"Kim K, Kwak BO, Kwon A, Ha J, Kim SJ, Bae SW, et al. Analysis of plasma multiplex cytokines and increased level of IL-10 and IL-1Ra cytokines in febrile seizures. J Neuroinflammation. 2017;14(1):200\u2013017.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"1825_CR25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-3083.2012.02710.x","volume":"76","author":"YA Youn","year":"2012","unstructured":"Youn YA, Kim SJ, Sung IK, Chung SY, Kim YH, Lee IG. Serial examination of serum IL-8, IL-10 and IL-1Ra levels is significant in neonatal seizures induced by hypoxic-ischaemic encephalopathy. Scand J Immunol. 2012;76(3):286\u201393.","journal-title":"Scand J Immunol"},{"issue":"6","key":"1825_CR26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ane.12665","volume":"135","author":"F Gao","year":"2017","unstructured":"Gao F, Gao Y, Zhang SJ, Zhe X, Meng FL, Qian H, et al. Alteration of plasma cytokines in patients with active epilepsy. Acta Neurol Scand. 2017;135(6):663\u20139.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1825_CR27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/seiz.2001.0575","volume":"11","author":"J Peltola","year":"2002","unstructured":"Peltola J, Laaksonen J, Haapala AM, Hurme M, Rainesalo S, Keranen T. Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure. 2002;11(1):44\u20136.","journal-title":"Seizure"},{"key":"1825_CR28","doi-asserted-by":"crossref","first-page":"434010","DOI":"10.1155\/2013\/434010","volume":"2013","author":"G Kleiner","year":"2013","unstructured":"Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediat Inflamm. 2013;2013:434010.","journal-title":"Mediat Inflamm"},{"issue":"4","key":"1825_CR29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1590\/1516-4446-2014-1452","volume":"37","author":"M Gazal","year":"2015","unstructured":"Gazal M, Jansen K, Souza LD, Oses JP, Magalhaes PV, Pinheiro R, et al. Association of interleukin-10 levels with age of onset and duration of illness in patients with major depressive disorder. Braz J Psychiatry. 2015;37(4):296\u2013302.","journal-title":"Braz J Psychiatry"},{"issue":"5","key":"1825_CR30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/00207454.2017.1389928","volume":"128","author":"FI Tezer","year":"2018","unstructured":"Tezer FI, Firat A, Tuzun E, Unal I, Soylemezoglu F, Bilginer B, et al. Immunopathology in drug resistant mesial temporal lobe epilepsy with different types of hippocampal sclerosis. Int J Neurosci. 2018;128(5):421\u20138.","journal-title":"Int J Neurosci"},{"issue":"2","key":"1825_CR31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1212\/01.WNL.0000031792.89992.EC","volume":"60","author":"AT Berg","year":"2003","unstructured":"Berg AT, Langfitt J, Shinnar S, Vickrey BG, Sperling MR, Walczak T, et al. How long does it take for partial epilepsy to become intractable? Neurology. 2003;60(2):186\u201390.","journal-title":"Neurology"},{"issue":"10","key":"1825_CR32","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaneurol.2019.1708","volume":"76","author":"M Galovic","year":"2019","unstructured":"Galovic M, van Dooren VQH, Postma T, Vos SB, Caciagli L, Borzi G, et al. Progressive cortical thinning in patients with focal epilepsy. JAMA Neurol. 2019;76(10):1230\u20139.","journal-title":"JAMA Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01825-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01825-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01825-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T23:50:17Z","timestamp":1666914617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01825-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01825-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Tampere University Hospital approved the study (Ethics certification no. R02135) and all participants gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}